Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.61 |
| ▸ | MAOB | P27338 | 6/20 | 0.60 |
| ▸ | MAOA | P21397 | 3/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21748609 | 0.91 | MAP4K4 (0.62) | NR4A2MAOBMAOAMAP4K4PPARA | |
| SCHEMBL21991957 | 0.86 | MAP4K4 (0.58) | NR4A2MAP4K4PPARAPPARG | |
| SCHEMBL21992687 | 0.86 | MAOB (0.57) | NR4A2MAOBMAOAAPPPPARA | |
| SCHEMBL21991607 | 0.86 | PPARA (0.62) | NR4A2MAOBMAOAAPPPPARA | |
| SCHEMBL21991555 | 0.84 | PPARA (0.61) | NR4A2MAOBMAOAMAP4K4PPARA | |
| SCHEMBL21992686 | 0.83 | MAOB (0.55) | NR4A2MAOBMAOAAPPPPARA | |
| SCHEMBL21992667 | 0.83 | L3MBTL1 (0.55) | NR4A2MAOBMAOAMAP4K4PPARA | |
| SCHEMBL21991326 | 0.83 | MAOB (0.64) | NR4A2MAOBPPARAHRH3FFAR1 | |
| SCHEMBL21992684 | 0.82 | MAOB (0.53) | NR4A2MAOBMAOAAPPPPARA | |
| SCHEMBL21991803 | 0.82 | PPARA (0.73) | NR4A2MAOBMAOAPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | NR4A2 1549/4885MAOB 3946/4885MAOA 3996/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | NR4A2 1549/4885MAOB 3946/4885MAOA 3996/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | NR4A2 1549/4885MAOB 3946/4885MAOA 3996/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | NR4A2 1549/4885MAOB 3946/4885MAOA 3996/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | NR4A2 1549/4885MAOB 3946/4885MAOA 3996/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | NR4A2 1549/4885MAOB 3946/4885MAOA 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.